The DOI matches its Crossref record.
Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, north american trial
Abstract
OBJECTIVES: This multicenter, randomized, active-controlled trial assessed efficacy of bismuth-based quadruple therapy with omeprazole, bismuth biskalcitrate, metronidazole, and tetracycline (OBMT) using a single-triple capsule of BMT compared with triple therapy with omeprazole, amoxicillin, and clarithromycin (OAC) in treatment of patients with Helicobacter pylori infection and duodenal ulcers. METHODS: Patients with active duodenal ulcer or diagnosed within the past 5 yr and with infection documented by (13)C-urea breath test plus histology or culture were randomly assigned to 10-day course of OBMT using a single-triple capsule containing bismuth biskalcitrate 140 mg, metronidazole 125 mg, and tetracycline 125 mg given as three capsules q.i.d. with omeprazole 20 mg b.i.d., or a 10-day course of OAC, omeprazole 20 mg plus amoxicillin 1 g plus clarithromycin 500 mg, all b.i.d. Eradication was confirmed by two negative urea breath tests at >1 month and >2 months after therapy. RESULTS: One hundred thirty-eight patients received OBMT and 137 OAC. Modified intent-to-treat eradication rates were 87.7% for OBMT and 83.2% for OAC (95% CI = -3.9%-12.8%; p = 0.29). OBMT eradicated 91.7% metronidazole-sensitive and 80.4% metronidazole-resistant strains (p = 0.06). OAC eradicated 92.1% clarithromycin sensitive and 21.4% clarithromycin-resistant strains (p < 0.001). Adverse events occurred in 58.5% of OBMT patients and 59.0% of OAC patients. CONCLUSIONS: OBMT regimen using the single-triple capsule is as efficacious and well-tolerated as the widely used OAC regimen for H. pylori eradication. This OBMT therapy largely overcomes H. pylori metronidazole resistance, present in 40% of patients in this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
Malfertheiner, P., Megraud, F., O'Morain, C. A., Gisbert, J. P., Kuipers, E. J., Axon, A. T., Bazzoli, F., Gasbarrini, A., Atherton, J., Graham, D. Y., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312288 · Cited by 2,946
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
Malfertheiner, P., Megraud, F., O'Morain, C. A., Atherton, J., Axon, A. T. R., Bazzoli, F., Gensini, G. F., Gisbert, J. P., Graham, D. Y., Rokkas, T., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-302084 · Cited by 2,266
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.563 · Cited by 1,604
American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection
Chey, W. D., Wong, B. C. Y., & Practice Parameters Committee of the American College of Gastroenterology (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01393.x · Cited by 1,406
H pylori antibiotic resistance: prevalence, importance, and advances in testing
Mégraud, F. (2004) · Gut · doi:10.1136/gut.2003.022111 · Cited by 955
Metadata
- Authors
- Laine, L.
- Venue
- The American Journal of Gastroenterology
- Published
- 2003-03
- Volume
- 98
- Issue
- 3
- Pages
- 562-567
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2170048761
- Cited by
- 240
- References
- 0
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, north american trial. https://app.cochat.ai/papers/10.1016/s0002-9270(02)06010-0
- The paper
- Laine, L. (2003). Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, north american trial. The American Journal of Gastroenterology. https://doi.org/10.1016/s0002-9270(02)06010-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.